Bruce N. Jacobs, CFO of Kymera Therapeutics ($KYMR), made eight open market sales of company shares over the last year, totaling $5.1 million. His most recent sale occurred on March 4, 2026. These transactions rank 1920th among 11,678 insiders by total value sold, trailing the average of $8.6 million across 6.4 sales per insider. Jacobs reported no open market purchases in the period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 2, 2026 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | A | Common Stock | 17650 | $0.00 | 245,059.0000 | 87,300,286 | 7.76% | 0.02% |
| March 2, 2026 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | A | Stock Option (Right to Buy) | 35300 | $0.00 | 35,300.0000 | 87,300,286 | 9999.99% | 0.04% |
| March 4, 2026 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | S | Common Stock | 447 | $86.62 | 232,588.0000 | 87,300,286 | 0.19% | 0.00% |
| March 4, 2026 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | S | Common Stock | 1437 | $85.78 | 233,035.0000 | 87,300,286 | 0.61% | 0.00% |
| March 4, 2026 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | S | Common Stock | 2519 | $85.04 | 234,472.0000 | 87,300,286 | 1.06% | 0.00% |
| March 4, 2026 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | S | Common Stock | 492 | $84.00 | 236,991.0000 | 87,300,286 | 0.21% | 0.00% |
| March 2, 2026 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | S | Common Stock | 4113 | $89.66 | 237,483.0000 | 87,300,286 | 1.70% | 0.00% |
| March 2, 2026 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | S | Common Stock | 1424 | $88.50 | 241,596.0000 | 87,300,286 | 0.59% | 0.00% |
| March 2, 2026 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | S | Common Stock | 2039 | $87.75 | 243,020.0000 | 87,300,286 | 0.83% | 0.00% |
| Sept. 17, 2025 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | M | Stock Option (Right to Buy) | 42246 | $0.00 | 27,653.0000 | 75,043,991 | 60.44% | 0.06% |
| Sept. 17, 2025 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | M | Common Stock | 79220 | $2.08 | 306,629.0000 | 75,043,991 | 34.84% | 0.11% |
| Sept. 17, 2025 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | S | Common Stock | 79220 | $50.00 | 227,409.0000 | 75,043,991 | 25.84% | 0.11% |
| Sept. 17, 2025 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | M | Stock Option (Right to Buy) | 36974 | $0.00 | 0.0000 | 75,043,991 | 100.00% | 0.05% |
| March 31, 2025 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | M | Common Stock | 25000 | $2.08 | 226,886.0000 | 75,043,991 | 12.38% | 0.03% |
| March 31, 2025 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | M | Stock Option (Right to Buy) | 25000 | $0.00 | 69,899.0000 | 75,043,991 | 26.34% | 0.03% |
| March 3, 2025 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | S | Common Stock | 1281 | $31.00 | 201,886.0000 | 75,043,991 | 0.63% | 0.00% |
| March 3, 2025 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | A | Stock Option (Right to Buy) | 60000 | $0.00 | 60,000.0000 | 75,043,991 | 9999.99% | 0.08% |
| March 3, 2025 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | S | Common Stock | 5754 | $30.33 | 203,167.0000 | 75,043,991 | 2.75% | 0.01% |
| March 3, 2025 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | A | Common Stock | 30000 | $0.00 | 208,921.0000 | 75,043,991 | 16.77% | 0.04% |
| Jan. 10, 2025 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | M | Stock Option (Right to Buy) | 10000 | $0.00 | 94,899.0000 | 75,043,991 | 9.53% | 0.01% |
| Jan. 10, 2025 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | M | Common Stock | 10000 | $2.08 | 178,921.0000 | 75,043,991 | 5.92% | 0.01% |
| June 27, 2024 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | M | Common Stock | 25000 | $2.08 | 168,554.0000 | 58,365,499 | 17.42% | 0.04% |
| June 27, 2024 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | M | Stock Option (Right to Buy) | 25000 | $0.00 | 104,899.0000 | 58,365,499 | 19.25% | 0.04% |
| March 4, 2024 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | S | Common Stock | 255 | $43.26 | 142,351.0000 | 58,365,499 | 0.18% | 0.00% |
| March 1, 2024 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | A | Stock Option (Right to Buy) | 187500 | $0.00 | 187,500.0000 | 58,365,499 | 9999.99% | 0.32% |
| March 1, 2024 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | A | Common Stock | 31250 | $0.00 | 146,285.0000 | 58,365,499 | 27.17% | 0.05% |
| March 4, 2024 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | S | Common Stock | 2378 | $41.41 | 143,907.0000 | 58,365,499 | 1.63% | 0.00% |
| March 4, 2024 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | S | Common Stock | 1301 | $42.39 | 142,606.0000 | 58,365,499 | 0.90% | 0.00% |
| June 2, 2023 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | M | Stock Option (Right to Buy) | 10000 | $0.00 | 129,899.0000 | 53,933,229 | 8.34% | 0.02% |
| June 2, 2023 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | M | Common Stock | 10000 | $2.08 | 115,035.0000 | 53,933,229 | 9.52% | 0.02% |
| March 1, 2023 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | A | Common Stock | 23750 | $0.00 | 105,938.0000 | 53,933,229 | 28.90% | 0.04% |
| March 1, 2023 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | A | Stock Option (Right to Buy) | 142500 | $0.00 | 142,500.0000 | 53,933,229 | 9999.99% | 0.26% |
| March 2, 2023 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | S | Common Stock | 314 | $31.40 | 104,568.0000 | 53,933,229 | 0.30% | 0.00% |
| March 2, 2023 | Kymera Therapeutics, Inc. | $KYMR | Jacobs Bruce N. | Chief Financial Officer | S | Common Stock | 1056 | $30.88 | 104,882.0000 | 53,933,229 | 1.00% | 0.00% |